CLAIMS

1. A pharmaceutical composition for use in the treatment of a disease or condition caused by or associated with a virus belonging to the *Enterovirus* genus of the *Picornaviridae* family, comprising a therapeutically effective amount of at least one of nitazoxanide or tizoxanide or a pharmaceutically acceptable salt thereof.

2. The pharmaceutical composition of claim 1, for alleviating at least one symptom of the disease or condition, wherein the at least one symptom is selected from fever, cough, sore throat, nasal obstruction, fatigue, headache, myalgia, and feverishness.

3. The pharmaceutical composition of claim 2, for a) reducing fever caused by or associated with the disease or condition and b) alleviating at least one symptom of the disease or condition, wherein the at least one symptom is selected from cough, sore throat, nasal obstruction, fatigue, headache, myalgia, and feverishness.

4. The pharmaceutical composition of claim 3, for a) reducing the fever caused by or associated with the disease or condition, and b) alleviating at least one respiratory symptom caused by or associated with the disease or condition and at least one constitutional symptom associated with the disease or condition, wherein the at least one respiratory symptom is selected from cough, sore throat, and nasal obstruction

and wherein the at least constitutional symptom is selected from fatigue, headache, myalgia, and feverishness.

5. The pharmaceutical composition of claim 1, wherein the virus is selected from Enterovirus A-J.

6. The pharmaceutical composition of claim 1, wherein the virus is selected from Rhinovirus A-C.

7. The pharmaceutical composition of claim 1, a therapeutically effective amount of a direct-acting antiviral agent is to be further administered.

8. The pharmaceutical composition of claim 7, wherein the direct-acting antiviral agent is rupintrivir or MK-0608 or a pharmaceutically acceptable salt thereof.

9. The pharmaceutical composition of claim 1, wherein said pharmaceutical composition starts to be administered within 48 hours of an onset in a subject of at least one symptom of the disease or condition, wherein the at least one symptom is selected from fever, cough, sore throat, nasal obstruction, fatigue, headache, myalgia, and feverishness.

10. The pharmaceutical composition of claim 1, to be administered to a human.

11. The pharmaceutical composition of claim 1, wherein the composition reduces a time to alleviation of symptoms of the disease or condition.